Top Page
China Bozza Development Holdings Limited
(1069)
China Bozza Development Holdings Limited (1069) vs. iShares MSCI Hong Kong ETF (EWH)
China Bozza Development Holdings Limited Business Overview & Revenue Model
China Bozza Development Holdings Limited Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2024 | Dec 2022 | Jun 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 94.60M | 97.39M | 47.61M | 58.72M | 6.76M | 6.67M |
| Gross Profit | 8.62M | 8.87M | 1.90M | 11.51M | 0.00 | 6.67M |
| EBITDA | -7.74M | -7.74M | 208.39M | -42.17M | -9.85M | -48.36M |
| Net Income | 24.03M | 24.52M | 200.01M | -10.80M | -18.90M | -268.54M |
Balance Sheet | ||||||
| Total Assets | 225.04M | 191.09M | 178.17M | 140.64M | 93.52M | 491.54M |
| Cash, Cash Equivalents and Short-Term Investments | 4.92M | 2.68M | 3.23M | 4.33M | 1.11M | 134.00K |
| Total Debt | 127.45M | 115.23M | 119.11M | 356.77M | 321.97M | 333.44M |
| Total Liabilities | 173.86M | 166.22M | 165.20M | 457.35M | 400.15M | 369.48M |
| Stockholders Equity | 51.18M | 24.87M | 12.96M | -316.71M | -306.63M | 122.06M |
Cash Flow | ||||||
| Free Cash Flow | 1.77M | -959.71K | 28.63M | 22.16M | -466.00K | -5.58M |
| Operating Cash Flow | 1.77M | 37.43M | 28.86M | 23.44M | -466.00K | -5.58M |
| Investing Cash Flow | -6.15M | -38.34M | -26.49M | -23.26M | 2.00K | -410.00K |
| Financing Cash Flow | 3.83M | 2.29M | -3.47M | 3.04M | -249.00K | -3.29M |
China Bozza Development Holdings Limited Technical Analysis
China Bozza Development Holdings Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$1.40B | 7.44 | 3.56% | 3.45% | -5.66% | -56.96% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
50 Neutral | HK$43.74M | 1.47 | 75.10% | ― | 88.72% | -91.59% | |
49 Neutral | HK$60.92M | 14.15 | 0.85% | ― | -5.06% | ― | |
46 Neutral | HK$5.25B | -0.22 | ― | ― | -76.55% | -966.54% | |
46 Neutral | HK$170.00M | 6.63 | 2.13% | 6.11% | 0.80% | 81.27% | |
45 Neutral | HK$240.48M | 13.93 | 11.34% | ― | -9.44% | ― |
China Bozza Development Holdings Limited Corporate Events
China Health Technology Group Holding Company Limited has issued a supplemental announcement correcting clerical errors in the disclosed poll results for two ordinary resolutions at its 31 December 2025 annual general meeting, specifically those relating to authorising the board to fix directors’ remuneration and to re-appoint the company’s auditor, Jon Gepsom CPA Limited, and authorise the board to fix its remuneration; the corrected figures confirm both resolutions were passed with 100% of votes cast in favour. The company also rectified a mislabelled heading regarding changes in board committee composition, clarifying that it pertains to the composition of all board committees rather than only the nomination committee, while emphasising that all other information from the original announcement remains unchanged, thereby seeking to reassure investors about the accuracy of its governance disclosures.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.46 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.
Shareholders of China Health Technology Group Holding Company Limited approved all resolutions at the 31 December 2025 annual general meeting, including adoption of the 2025 financial statements, director remuneration, reappointment of Jon Gepsom CPA Limited as auditor, and general mandates for the board to issue up to 20% and repurchase up to 10% of the company’s share capital, as well as an extension mandate and the adoption of a new share scheme. The results, all passed by poll with 100% support on votes cast, also confirmed board changes through the re-election or rejection of certain directors and signalled continued support for the company’s capital management flexibility and equity-based incentive arrangements, with implications for future share issuance and governance structure; the company simultaneously disclosed pending changes to the chairman role, board committees and a period of non-compliance with listing rules, underscoring ongoing governance adjustments closely watched by investors.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.46 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.
China Health Technology Group Holding Company Limited has announced the current composition of its board of directors, naming Ms. Bu Xue as executive director, chairman and chief executive officer, alongside independent non-executive directors Mr. Chau Wing Nam and Ms. Liu Shuhua. The company also clarified the structure and membership of its three main board committees, with Mr. Chau chairing the audit, remuneration and nomination committees, and Ms. Bu and Ms. Liu serving as members, underscoring the firm’s governance framework and the role of independent oversight in its board operations.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.46 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.
China Health Technology Group Holding Company Limited has announced its upcoming annual general meeting scheduled for December 31, 2025, in Hong Kong. The meeting will address several key agenda items, including the adoption of audited financial statements, re-election of directors, and re-appointment of auditors. Additionally, resolutions will be considered to authorize the board to manage share allotments and directors’ remuneration, reflecting the company’s ongoing governance and operational strategies.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.
China Bozza Development Holdings Limited has proposed the adoption of a Share Scheme aimed at aligning the long-term interests of its directors and key employees with the company’s growth. This initiative, pending shareholder approval, is designed to incentivize continuous development and will be detailed in a forthcoming circular to shareholders. The adoption of the Share Scheme is contingent upon approval at the AGM and the Stock Exchange’s consent for listing new shares, potentially impacting the company’s operational dynamics and stakeholder engagement.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.
China Health Technology Group Holding Company Limited announced the resignation of Mr. Wang Yibin from his roles as Executive Director and Chief Executive Officer, effective December 1, 2025, due to other business commitments. The company has appointed Ms. Bu Xue as the new Chief Executive Officer, highlighting her extensive experience in marketing and business development, and her qualifications in accounting and tax advisory. This leadership change is expected to bring fresh perspectives to the company, potentially impacting its strategic direction and operations.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.
China Health Technology Group Holding Company Limited has announced the composition of its board of directors, which includes both executive and independent non-executive directors. The announcement also details the membership of various board committees, highlighting the roles and responsibilities of each director within these committees.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.